Zoya N Demidenko
First author of the 2009 Cell Cycle study showing that rapamycin slows cellular senescence.
Roswell Park Cancer Institute, Buffalo, NY · Oncotarget, Albany, NY
Zoya N Demidenko is first author of the 2009 Cell Cycle study (DEM2009). In human and rodent cell lines, the team blocked the cell cycle and let cell growth continue, which pushed cells into permanent senescence. Rapamycin kept the arrested cells able to start dividing again once the block was removed. This is evidence that mTOR helps drive the senescent state. PubMed lists her with Mikhail Blagosklonny on more than 30 papers, and on the 2011 and 2015 papers on rapamycin and senescence her affiliation is the Department of Cell Stress Biology at Roswell Park Cancer Institute in Buffalo, New York.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2009 | M | Rapamycin decelerates cellular senescence DEM2009 First author of the cell-line study showing that rapamycin decelerates cellular senescence. |
Co-authors in the Atlas 1
People with a profile here who share at least one study with Zoya N Demidenko.
ShowHide
- Mikhail V. Blagosklonny Proposed the hyperfunction theory of ageing: TOR signalling that builds a young body never fully switches off, and drives its ageing instead
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.